Go Pro
NASDAQ:PMVP

PMV Pharmaceuticals Q2 2026 Earnings Report

PMV Pharmaceuticals logo
$1.28 +0.04 (+3.23%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$1.28 0.00 (0.00%)
As of 08:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.38
Beat/Miss
N/A
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 7, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

PMV Pharmaceuticals Earnings Headlines

They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.tc pixel
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile